KALA - Kala Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
9.86
-0.08 (-0.80%)
At close: 4:00PM EDT

9.86 0.00 (0.00%)
After hours: 4:26PM EDT

Stock chart is not supported by your current browser
Previous Close9.94
Open9.71
Bid9.65 x 800
Ask10.00 x 800
Day's Range9.55 - 10.04
52 Week Range7.60 - 22.10
Volume407,923
Avg. Volume365,096
Market Cap327.665M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.55
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.20
Trade prices are not sourced from all markets
  • Business Wire2 days ago

    Kala Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for KPI-121 0.25% for Dry Eye Disease

    Kala Pharmaceuticals, Inc. (Kala) (KALA), today announced that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for KPI-121 0.25%, a topical product candidate which, if approved, could be the first FDA-approved product for the temporary relief of signs and symptoms of dry eye disease. There are an estimated 33 million patients with dry eye disease in the U.S. and Kala’s market research indicates that approximately 90% of these patients have flares associated with their dry eye disease. KPI-121 0.25% utilizes Kala’s AMPPLIFYTM mucus-penetrating particle (MPP) Drug Delivery Technology, which are selectively-sized nanoparticles with proprietary coatings that significantly enhance drug penetration and distribution in ocular tissues.

  • Business Wire6 days ago

    Kala Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares

    Kala Pharmaceuticals, Inc. , a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle technology, announced today that the underwriters of its previously announced public offering have exercised in full their option to purchase an additional 1,125,000 shares of common stock at the public offering price of $8.25 per ...

  • Kala Pharmaceuticals (KALA) Catches Eye: Stock Jumps 7.4%
    Zacks9 days ago

    Kala Pharmaceuticals (KALA) Catches Eye: Stock Jumps 7.4%

    Kala Pharmaceuticals (KALA) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

  • Here's Why Kala Pharmaceuticals Fell as Much as 17.7% Today
    Motley Fool14 days ago

    Here's Why Kala Pharmaceuticals Fell as Much as 17.7% Today

    The pharma company announced the pricing of a share offering.

  • Business Wire15 days ago

    Kala Pharmaceuticals Announces Financing from Athyrium Capital Management Totaling $110 Million

    Kala Pharmaceuticals, Inc. (KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, today announced the closing of Kala’s $110 million credit facility with funds managed by Athyrium Capital Management, LP, a leading healthcare focused investment firm. “We are pleased to be partnering with Athyrium and to have their support and confidence in INVELTYS for the treatment of inflammation and pain following ocular surgery and KPI-121 0.25% for dry eye disease,” said Mark Iwicki, Chairman, President and Chief Executive Officer of Kala Pharmaceuticals.

  • Business Wire15 days ago

    Kala Pharmaceuticals Announces Proposed Public Offering of Common Stock

    Kala Pharmaceuticals, Inc. (“Kala”) (KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, announced today that it has commenced an underwritten public offering of 7,500,000 shares of its common stock. Kala also intends to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional 1,125,000 shares of common stock offered in the public offering at the public offering price, less the underwriting discount.

  • Is Kala Pharmaceuticals Inc’s (NASDAQ:KALA) Balance Sheet A Threat To Its Future?
    Simply Wall St.21 days ago

    Is Kala Pharmaceuticals Inc’s (NASDAQ:KALA) Balance Sheet A Threat To Its Future?

    Kala Pharmaceuticals Inc (NASDAQ:KALA) is a small-cap stock with a market capitalization of US$266.8m. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they Read More...

  • Business Wire26 days ago

    Kala Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Kala Pharmaceuticals, Inc. (KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 69,500 shares of Kala Pharmaceuticals common stock to seven new employees.

  • TheStreet.comlast month

    Six Biotechnology Names on My Watch List

    The indices have been slowly drifting lower after a gap up open. Early breadth was around 3 to 1 positive but its now down to around 4-3 positive. The bulls are not producing much positive momentum but the bears are doing an even worse job of producing negative momentum.

  • GlobeNewswire2 months ago

    Research Report Identifies Holly Energy Partners, First Merchants, Enbridge Energy Management, Activision Blizzard, Coherus BioSciences, and Kala Pharmaceuticals with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Aug. 31, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Holly ...

  • Business Wire2 months ago

    Kala Pharmaceuticals to Present at Upcoming Investor Conferences

    Kala Pharmaceuticals, Inc. , a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating parti

  • Biotech Stock Roundup: GILD Gets EC Nod for Yescarta, AMGN Submits Kyprolis sNDA
    Zacks2 months ago

    Biotech Stock Roundup: GILD Gets EC Nod for Yescarta, AMGN Submits Kyprolis sNDA

    Regulatory and pipeline updates comprise some of the key developments in the biotech sector this week. These include Gilead's Yescarta approval in Europe.

  • Reuters2 months ago

    U.S. FDA approves Kala Pharma's eye pain drug

    The U.S. Food and Drug Administration on Thursday approved Kala Pharmaceuticals Inc's treatment for reducing inflammation and pain following an eye surgery. The company said it expects to launch the drug, Inveltys, in the beginning of 2019, with Wedbush Securities estimating peak sales of about $271 million in 2027. The drug was found to have no serious side effects during clinical trials, Kala said.

  • MarketWatch2 months ago

    Kala stock declines 6% after FDA approves ocular surgery product

    Kala Pharmaceuticals Inc. (KALA) shares dropped 6% in Thursday afternoon trade after the Food and Drug Administration approved its corticosteroid for inflammation and pain after eye surgery. Having to dose a product four times a day "can be burdensome for patients as they are taking multiple eye drop products following surgery and is believed to reduce patient compliance," the company said. Kala plans a launch for early 2019, and said it will hire a specialty sales force to cater to U.S. eye care professionals.

  • H.C. Wainwright Maintains Buy on Kala Pharmaceuticals (KALA) Ahead of Upcoming PDUFA Date
    SmarterAnalyst2 months ago

    H.C. Wainwright Maintains Buy on Kala Pharmaceuticals (KALA) Ahead of Upcoming PDUFA Date

    H.C. Wainwright analyst Ram Selvaraju is out this morning with another bullish note on shares of Kala Pharmaceuticals (NASDAQ:KALA), reiterating a Buy rating and price target of $35, which represents a potential upside of 197% from where the stock is currently trading. Selvaraju continues to see a favorable risk/reward profile on Kala heading into the August 24 PDUFA date for lead candidate, INVELTYS. If approved, INVELTYS would be the first FDA-approved corticosteroid eye drop with a twice daily dosing regimen for the treatment of post-operative ocular inflammation and pain. In our view, the combination of LE’s safety profile and dosing convenience should allow INVELTYS to seize market share from branded eye drops such as Lotemax and Durezol, as well as generic prednisolone.

  • Associated Press2 months ago

    Kala Pharma: 2Q Earnings Snapshot

    The Waltham, Massachusetts-based company said it had a loss of 60 cents per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...

  • Business Wire2 months ago

    Kala Pharmaceuticals Reports Second Quarter 2018 Financial Results

    – PDUFA Target Action Date for INVELTYS™ is August 24, 2018 –

  • Business Wire2 months ago

    Kala Pharmaceuticals to Present at the Wedbush PacGrow Healthcare Conference

    Kala Pharmaceuticals, Inc. , a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle technology, today announced that it will present at the 2018 Wedbush PacGrow Healthcare Conference in New York, NY.

  • Kala Pharmaceuticals (KALA), Durect (DRRX), and Amarin (AMRN) Reiterated with a Buy at H.C. Wainwright
    SmarterAnalyst2 months ago

    Kala Pharmaceuticals (KALA), Durect (DRRX), and Amarin (AMRN) Reiterated with a Buy at H.C. Wainwright

    In a research note issued Wednesday, H.C. Wainwright analyst Ram Selvaraju reiterated coverage on shares of Kala Pharmaceuticals (NASDAQ:KALA), with a Buy rating and price target of $35, which represents a potential upside of 173% from where the stock is currently trading. The reiteration follows the news that the company's third phase 3 trial (STRIDE 3) of KPI-121 0.25% for the treatment of dry eye disease (DED), had dosed its first patient. Selvaraju wrote, "The STRIDE 3 trial design has specific modifications to the inclusion/exclusion criteria to address key factors that could improve the probability of success, according to management.

  • Business Wire3 months ago

    Kala Pharmaceuticals Announces Dosing of First Patient in Phase 3 STRIDE 3 Trial of KPI-121 0.25% in Patients with Dry Eye Disease

    Kala Pharmaceuticals, Inc. (KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, today announced that the first patient has been dosed in STRIDE 3 (Short Term Relief In Dry Eye), its Phase 3 trial of KPI-121 0.25% for the short-term treatment of dry eye disease. If approved, KPI-121 0.25% could be the first FDA-approved product for the short-term treatment of dry eye disease,” said Kim Brazzell, Chief Medical Officer. “The STRIDE 3 trial design reflects specific modifications to the inclusion/exclusion criteria of our previous trials to address key factors which we believe will improve the probability of success.

  • GlobeNewswire3 months ago

    Recent Analysis Shows Kala Pharmaceuticals, Integer, Carnival, Coty, Sykes Enterprises, and Agilent Technologies Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, July 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Kala ...

  • According to H.C. Wainwright, This Biotech Stock Can Jump to $35
    SmarterAnalyst3 months ago

    According to H.C. Wainwright, This Biotech Stock Can Jump to $35

    It's been tough sledding for Kala Pharmaceuticals (NASDAQ:KALA) shareholders. The company's share price has lost approximately 46% year-to-date due to the fact that its second Phase 3 trial in dry eye disease (DED) did not meet the symptom endpoint. Since this candidate is based on a well-known, validated corticosteroid that has been used for many years in ocular applications, and given the fact that the NDA was filed via the 505(b)(2) regulatory pathway, Selvaraju has high confidence that INVELTYS should be approved by August 24 (the PDUFA date).

  • Kala Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
    Zacks3 months ago

    Kala Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

    Kala Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

  • Options Traders Expect Huge Moves in Kala Pharmaceuticals (KALA) Stock
    Zacks4 months ago

    Options Traders Expect Huge Moves in Kala Pharmaceuticals (KALA) Stock

    Investors in Kala Pharmaceuticals (KALA) need to pay close attention to the stock based on moves in the options market lately.

  • Wedbush Sees 240% Upside for Kala Pharmaceuticals (KALA) Stock; Here’s Why
    SmarterAnalyst4 months ago

    Wedbush Sees 240% Upside for Kala Pharmaceuticals (KALA) Stock; Here’s Why

    Wedbush analyst Liana Moussatos is out today with a bullish note on shares of Kala Pharmaceuticals (NASDAQ:KALA), following the drug maker's announcement that it plans to submit a New Drug Application (NDA) to the FDA for its dry eye treatment KPI-121 0.25% during the second half of 2018, while initiating an additional Phase 3 trial (STRIDE 3) in the third-quarter of this year, as per FDA suggestion.